Inhaled corticosteroids for the treatment of COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.
Puedes leer el artículo completo en este enlace: https://err.ersjournals.com/content/31/166/220099
Noticias relacionadas con la COVID-19
Entrevista SEMG al Dr. Alvar Agusti, Experto en la II Jornada Resprimaria
Descubre los avances en el diagnóstico y tratamiento de la EPOC con el Dr. Alvar Agustí en la II Jornada SEMG Resprimaria. Conoce la importancia de la espirometría, la detección precoz y las nuevas estrategias terapéuticas.
Monitoring and assessment of CO2 and NO2 in schools within the Sentinel Schools Network of Catalonia during the COVID-19 era
Explore how the COVID-19 Sentinel Schools Network of Catalonia monitored CO2 and NO2 levels in classrooms, revealing key findings on ventilation and air quality in schools across Catalonia during the pandemic.
Organizing Pneumonia in Hospitalized COVID-19 Patients: Risk Factors and Long-term Outcomes
Some patients develop post-COVID organizing pneumonia (OP), which is responsiveto treatment with corticosteroids.
Últimos 5 enlaces a artículos de COVID-19 en esta web:
COVID19
- 20220307·Cruz, T., et al., SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae. ERJ Open Research, 2022. 8(1): p. 00706-2021
- 769491·Tamara Cruz, Núria Mendoza, Gema M Lledó, Lídia Perea, Núria Albacar, Alvar Agustí, Jacobo Sellares, Oriol Sibila, Rosa Faner. Persistence of a SARS-CoV-2 T-cell response in patients with long COVID and lung sequelae after COVID-19
- 778991·Mona Bafadhel, Rosa Faner, Camille Taillé, Richard E.K. Russell, Tobias Welte, Peter J. Barnes and Alvar Agustí. Inhaled corticosteroids for the treatment of COVID-19
- 779199· Bartolome Celli et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision
- 779385·Alvar Agustí, Esther Pallisa, Domingo Escudero, Manel Escobar. Propuestas JANUS para la mejora de la experiencia de la persona atendida en consultas externas
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría COVID en esta web.
También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen obtenida del artículo original el 7.12.22